Analysts expect that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will announce sales of $16.07 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from $12.10 million to $23.40 million. Agios Pharmaceuticals posted sales of $22.65 million in the same quarter last year, which suggests a negative year-over-year growth rate of 29.1%. The company is scheduled to issue its next earnings results on Thursday, February 15th.
On average, analysts expect that Agios Pharmaceuticals will report full-year sales of $16.07 million for the current fiscal year, with estimates ranging from $45.30 million to $56.60 million. For the next financial year, analysts forecast that the company will report sales of $115.02 million per share, with estimates ranging from $60.08 million to $232.90 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.78) by $0.19. The business had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.63) EPS.
In other news, insider Scott Biller sold 2,146 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total value of $134,532.74. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO David P. Schenkein sold 53,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the completion of the sale, the chief executive officer now directly owns 53,000 shares in the company, valued at $3,877,480. The disclosure for this sale can be found here. Insiders have sold a total of 80,130 shares of company stock worth $5,561,250 over the last three months. Insiders own 5.43% of the company’s stock.
Several large investors have recently bought and sold shares of AGIO. QS Investors LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at $144,000. State of Alaska Department of Revenue bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at $160,000. Cubist Systematic Strategies LLC boosted its stake in shares of Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 3,123 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Agios Pharmaceuticals by 74.8% in the 4th quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 1,520 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in shares of Agios Pharmaceuticals in the 3rd quarter valued at $225,000. 94.32% of the stock is currently owned by institutional investors.
Agios Pharmaceuticals (NASDAQ AGIO) traded down $2.18 during mid-day trading on Friday, reaching $68.15. 968,100 shares of the company were exchanged, compared to its average volume of 706,608. The firm has a market cap of $3,480.00, a PE ratio of -10.87 and a beta of 1.83. Agios Pharmaceuticals has a twelve month low of $39.24 and a twelve month high of $76.02.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/19/agios-pharmaceuticals-inc-agio-expected-to-announce-quarterly-sales-of-16-07-million.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.